Invivyd to pursue EUA for pemivibart for COVID-19 treatment in immunocompromised

Invivyd, Inc.

Plans EUA submission for pemivibart to treat mild-to-moderate COVID-19 in moderately-to-severely immunocompromised people via immunobridging pathway.
Immunobridging relies on Phase 2/3 STAMP trial data with adintrevimab and ongoing CANOPY trial for pemivibart PrEP.
Manufacturing plan targets ~100,000 doses available through H2 2024 to serve both PrEP and potential treatment uses.
2024 net product revenue guidance remains $150-200M; year-end cash at least $75M, excluding potential treatment sales.
After EUA submission, plans to initiate confirmatory safety, PK, and clinical virology trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.